NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









HighField Biopharmaceuticals

HighField Biopharmaceuticals

Private
HangzhouHealthcare & Life Scienceshttps://highfieldbio.com/

Last Round

VC Round

Aug 8, 2024

Total Funding Raised

$15.7M

Company Overview

HighField Biopharmaceuticals is a clinical-stage biotechnology company that develops novel lipid-based therapeutics, including immunoliposomes and lipid nanoparticles, for the treatment of cancer, diabetes, and other complex diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

lipid nanoparticleLNPdrug delivery platformbiotechmRNA deliveryantibody-drug conjugateADCT cell engagergene therapyoncology therapeuticsGMP manufacturingdrug discoveryclinical-stage biotechprecision medicinedrug design AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HighField Biopharmaceuticals Comparables

Compare HighField Biopharmaceuticals with similar companies based on industry and business-model similarity.

HighField Biopharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Acuitas Therapeutics
75%
NanoVation Therapeutics
75%
Genevant Sciences
70%

HighField Biopharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 8, 2024
Series BDec 22, 2021
Series ASep 10, 2019
AngelDec 15, 2017

HighField Biopharmaceuticals Investors

Notable investors and investment history

HighField Biopharmaceuticals investors
InvestorRounds
杭州金投产业基金管理有限公司Series B
Hiway CapitalSeries B, Series A
Hangzhou Finance and Investment GroupSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 10, 2019

    Raised Series A with Hiway Capital and Hangzhou Tigermed.

HighField Biopharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HighField Biopharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HighField Biopharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range2
Year Founded2013
Last FundingAug 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.